Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206158 | 0.92 | MAPT (0.34) | PPARGHPGDPPARAGAAMAPT | |
| SCHEMBL26206404 | 0.90 | LTB4R (0.37) | IDO1MAPTMPO | |
| SCHEMBL27015403 | 0.86 | ADRB2 (0.39) | PPARGADRB2ADRB1HTR1AMPO | |
| SCHEMBL27015423 | 0.84 | ADRB2 (0.39) | PPARGADRB2ADRB1HTR1AMPO | |
| SCHEMBL26206173 | 0.83 | HDAC8 (0.34) | PPARGHPGDPPARAMAPTADRB2 | |
| SCHEMBL22526261 | 0.82 | AAK1 (0.41) | PPARG | |
| SCHEMBL26206133 | 0.82 | MPO (0.33) | PPARGPPARAMAPTADRB2MEN1 | |
| SCHEMBL26206174 | 0.82 | MPO (0.35) | PPARGHPGDPPARAADRB2ADRB1 | |
| SCHEMBL26206406 | 0.81 | FOS (0.35) | MAPT | |
| SCHEMBL26253853 | 0.80 | PLA2G2C (0.34) | IDO1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PPARG 1830/4885HPGD 2060/4885IDO1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.